Legend Biotech (LEGN) Liabilities and Shareholders Equity (2019 - 2025)

Legend Biotech has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $1.7 billion in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 3.8% year-over-year to $1.7 billion; the trailing twelve-month figure through Dec 2025 stood at $6.8 billion (down 3.25% YoY), and the FY2025 full-year result was $1.7 billion, up 3.8% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $1.7 billion, up from $1.7 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $875.1 billion in Q2 2021, with the low at $813.8 million in Q3 2021.
• Historically, Liabilities and Shareholders Equity has averaged $84.2 billion across 5 years, with a median of $1.7 billion in 2025.
• The largest YoY upside for Liabilities and Shareholders Equity was 55.03% in 2021 against a maximum downside of 99.89% in 2021.
• Legend Biotech's Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then advanced by 18.89% to $1.3 billion in 2022, then surged by 38.89% to $1.8 billion in 2023, then retreated by 9.65% to $1.7 billion in 2024, then grew by 3.8% to $1.7 billion in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.7 billion (Q2 2025), per Business Quant data.